FDA recalls, laboratory analyses, and public-health investigations documenting contamination, adulteration, microbial hazards, and toxic metal exposure in commercial kratom products.
199 cases, 41 states, 54 hospitalizations. FDA tested 76 samples; 55% positive for Salmonella. Whole genome sequencing showed extreme genetic diversity, indicating widespread contamination from multiple sources. The FDA issued its first‑ever mandatory recall order against Triangle Pharmataturals.
Read outbreak report →Vanguard Enterprises (dba Bedrock MFG) recalled Monarch Premium Kratom in October 2025 after Florida state testing found Salmonella. Earlier recalls involved Club 13, Badger Botanicals, Zakah Life, Gaia Ethnobotanical, PDX Aromatics, and others — all due to Salmonella contamination in finished kratom powders and capsules.
Latest recall (2025) →FDA analysis of raw kratom materials from Kratom NC found Klebsiella pneumoniae, Enterobacter spp., and Escherichia sp. in finished products. The company refused to recall, prompting an FDA consumer warning. These findings demonstrate persistent breaches of basic food safety standards.
View FDA warning →| Metal | Concentration range (ng/g) | Safe daily exposure threshold (pharmaceuticals) |
|---|---|---|
| Lead (Pb) | Up to 2,700 ng/g (2.7 µg/g) | 5 µg/day (oral) |
| Nickel (Ni) | Up to 29,000 ng/g (29 µg/g) | ~20 µg/day (PDE) |
| Chromium (Cr) | Up to 60,000 ng/g (60 µg/g) | ~120 µg/day (Cr VI limits) |
| Arsenic (As) | Detected in multiple samples | 15 µg/day |
Heavy kratom users (≥8 g/day) can exceed safe lead intake by 432%. Chronic exposure is linked to nervous system damage, hypertension, kidney injury, and increased cancer risk. FDA posters and lab analyses confirm these findings across 30+ retail products.
FDA warning letters (2018‑2022) documented kratom products adulterated with tianeptine – an antidepressant not approved in the US with opioid‑like abuse liability. Products such as Tianaa Red/White/Green were sold as “kratom” but contained dangerous synthetic drugs. In other cases, “Detox Plus” was found to contain hidden tadalafil (Cialis) and kratom alkaloids.
FDA tianeptine warning →FDA issued a warning letter to Hydroxie, LLC (June 2025) for selling 7‑hydroxymitragynine products with unproven claims, stating that 7‑OH is “more potent than mitragynine” and raises serious safety concerns including addiction, withdrawal, and death. Unlabeled 7‑OH products evade consumer knowledge and increase overdose risk.
Read Hydroxie warning →Independent laboratory testing of commercial kratom extract shots and tinctures has repeatedly detected ethanol exceeding USP <467> residual solvent limits for ingestible products (5,000 ppm). Some products were found to contain ethanol between 15.7% and 16.15% — equivalent to standard liquor, yet sold in gas stations without age verification or alcohol labeling. The Kansas Alcoholic Beverage Control Division investigated these products, seized inventory, and determined they legally qualify as alcoholic beverages, leading to enforcement actions against retailers.
This hidden ethanol exposure poses several public health threats: consumers inadvertently ingest intoxicating levels of alcohol; potential for dangerous drug‑alcohol interactions (respiratory depression, liver stress); and complete circumvention of state alcohol regulations. Manufacturers exploit the lack of kratom‑specific CGMPs to avoid disclosure, leaving consumers unaware of both psychoactive solvent content and regulatory evasion.
FDA Import Alert 54-15 authorizes detention of all kratom‑containing dietary supplements at U.S. ports. Repeated warning letters cite lack of sterilization, no lot traceability, and failure to test for pathogens/heavy metals. The industry’s voluntary GMP program does not prevent contamination — evidenced by Salmonella recalls from “cGMP certified” vendors.
Read Import Alert →In multiple recall notices, companies admitted “lack of sterilization processes” and “breakdown in production controls.” In the Triangle Pharmataturals case, the firm refused a voluntary recall, forcing FDA’s first mandatory recall order. Finished products contaminated with Salmonella and Klebsiella prove inadequate environmental monitoring.
Mandatory recall case →Adulteration with tianeptine, ethanol, and synthetic 7‑OH occurs without label disclosure. Many products lack batch‑specific certificates of analysis (COA). The absence of mandatory CGMPs allows manufacturers to omit residual solvent testing and heavy metal limits, directly contradicting basic food safety standards.
FDA official position →Analysis of 30+ kratom products found mitragynine levels varying from 3.9 mg/g to 62.1 mg/g — a 16‑fold difference. “Extract” shots can contain 7‑OH levels far above natural dried leaf, with some products intentionally boosted to increase potency. Consumers cannot reliably dose, leading to unintentional overdose, tolerance, and severe adverse events (respiratory depression, seizures, cardiac toxicity).
Variability also extends to heavy metal content and microbial loads. This instability makes it impossible for healthcare providers to predict effects, and for users to avoid cumulative toxic metal exposure. The FDA has consistently stated that “kratom is not a safe, benign plant” partly due to this extreme unpredictability.
Despite decades of contamination events, the kratom industry remains essentially self‑regulated. The FDA has issued import alerts, mandatory recalls, and dozens of warning letters, but without a federal scheduling or enforceable CGMP framework, contaminated products re‑enter the market via different distributors. The repeated Salmonella outbreaks (199 cases, 41 states), toxic metals exceeding safe daily limits, and hidden ethanol/tianeptine adulteration demonstrate that voluntary standards are insufficient.
Public health agencies face an enormous enforcement burden: thousands of smoke shops, gas stations, and online vendors selling kratom without lot traceability or mandatory testing. Interstate commerce amplifies the challenge. The data compiled by CDC, FDA, and state poison centers show that manufacturing instability and quality‑control failures are not rare anomalies but systemic features of the commercial kratom marketplace.
Conclusion: Regardless of broader pharmacology debates, the commercial kratom marketplace presents unresolved manufacturing, contamination, and product‑standardization concerns that pose a direct threat to consumer safety.
FDA laboratory analyses, independent studies, and state enforcement actions document that kratom products are frequently contaminated with Salmonella, Klebsiella, lead, nickel, undeclared ethanol, and synthetic adulterants (tianeptine, high‑potency 7‑OH). Manufacturing variability leads to unpredictable alkaloid concentrations, and quality‑control failures are systemic — not isolated. Without federal scheduling or enforceable CGMPs, consumers remain exposed to heavy metals, microbial pathogens, and hidden psychoactive ingredients. Public health agencies have documented hospitalizations, outbreak deaths, and chronic toxicity risks directly linked to these contamination and adulteration patterns. These data support the need for strict regulatory oversight and product standardization.
